Table 2.

-Homocysteine (µmol/l) and C-reactive protein (ng/l) levels of the participants during the study.

Group	A (unopposed estrogen, n = 30)			B (estrogen-progestin combination, n = 31)			C (placebo, n = 24)
	baseline	after*	Δ	baseline	after*	Δ	baseline	after*	Δ
Homocysteine (µmol/l)	8.8±3.5	6.9±2.5a	- 21.6±- 29.8b	9.6±3.4	8.4±3.1a	- 12.2±- 28.9c	9.7±3.4	11.3±5.3	16.5±55.1
C-reactive protein (mg/l)	3.0±2.0	6.0±5.5a	100.5±127.1 b	3.1±2.2	5.9±4.3 a	93.5±96.4c	3.2±1.4	4.0±2.1 a	25.5±48.9

*After six months of treatment; Δ =  [(value after treatment - baseline value)/baseline value * 100]. The statistical analyses showed no difference between the groups' baseline homocysteine and C-reactive protein levels; a – p<0.01 compared with baseline (Wilcox test); b – p<0.01 compared with Δ of the other groups (Kruskal-Wallis and Dunn tests); c – p<0.01 compared with Δ of Group C (Kruskal-Wallis and Dunn tests).